Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by DZ Bank

Merck & Co., Inc. (NYSE:MRK) was downgraded by DZ Bank from a “buy” rating to a “hold” rating in a report released on Tuesday, Briefing.com reports. They currently have a $153.00 target price on the stock. DZ Bank‘s price objective suggests a potential upside of 2.97% from the company’s previous close.

A number of other brokerages have also recently weighed in on MRK. Zacks Research cut Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Monday, October 19th. Cantor Fitzgerald lifted their target price on Merck & Co., Inc. from $145.00 to $155.00 and gave the company a “neutral” rating in a research note on Monday. Jefferies Financial Group boosted their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Citigroup boosted their target price on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. Finally, BMO Capital Markets increased their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. Seventeen investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $155.74.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $148.58 on Tuesday. The firm has a 50 day moving average of $146.82 and a 200 day moving average of $126.89. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $366.58 billion, a price-to-earnings ratio of 153.18, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. During the same quarter last year, the firm earned $2.58 EPS. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.81 earnings per share for the current fiscal year.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP David Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Richard Deluca sold 20,784 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares of the company’s stock, valued at $17,569,312.29. The trade was a 13.37% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Several institutional investors have recently added to or reduced their stakes in MRK. Curry Webb Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $29,000. Horizons Wealth Management bought a new stake in Merck & Co., Inc. in the third quarter valued at about $30,000. Bullseye Investment Management LLC acquired a new position in Merck & Co., Inc. in the second quarter worth about $27,000. Graney & King LLC raised its position in Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares in the last quarter. Finally, Foresight Capital Management Advisors Inc. bought a new position in Merck & Co., Inc. during the third quarter worth about $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck agreed to divest its contract development and manufacturing (CDMO) business to Lonza. The transaction could sharpen the focus of Merck’s Life Science segment, simplify the portfolio and provide the CDMO operation with a stronger platform for growth. Merck to Divest CDMO Business to Lonza
• Positive Sentiment: Merck is advancing its HIV franchise, including investigational once-weekly oral combination therapy and additional treatment and prevention regimens. The FDA has accepted supplemental applications for IDVYNSO, with a regulatory decision expected in 2027, giving investors potential future product catalysts as the company prepares new clinical data. Merck Pushes Ahead With Oral HIV Regimens
• Positive Sentiment: Merck’s personalized melanoma vaccine strategy remains a potential long-term growth driver for its oncology business, particularly if the approach helps reduce cancer recurrence. Merck’s Cancer Strategy Gets Personal
• Neutral Sentiment: Cantor Fitzgerald raised its Merck price target from $145 to $155 but kept a Neutral rating, citing the need to assess the scale and commercial performance of newer launches. Freedom Broker also raised its target, from $125 to $140, while retaining a Hold rating. Merck Stocks Decline With Higher Target
• Neutral Sentiment: ETF investors were net buyers of approximately $22 million of MRK on October 29, providing a modest technical demand signal. ETFs Bought $22 Million of Merck

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.